Psilocybin reduces symptoms in treatment resistant depression, trial results show
British medical journal November 2, 2022 DOI: 10.1136/bmj.o2623 via Semantic Scholar
Summary
AI-generated from the abstractA single 25 mg dose of psilocybin, given with psychological support, reduced depression scores more than a 1 mg control dose over 12 weeks in 233 patients with treatment-resistant depression. The 10 mg dose showed intermediate effects. Participants received the drug in calming, non-clinical rooms with a therapist present during the eight-hour psychedelic session and then returned home. The results suggest that psilocybin can be a useful treatment for this difficult-to-treat condition.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 233 |
| Population | Patients with treatment resistant depression |
| Keywords | Medicine Psychology |
| Citations | 5 |
| Key finding | A single 25 mg dose of psilocybin reduced depression scores more than a 1 mg control dose over 12 weeks in patients with treatment-resistant depression. |
Abstract
single a Researchers investigated the effects of single doses of 25 mg, 10 mg, or 1 mg (control) psilocybin over 12 weeks in 233 patients with treatment resistant depression. They were given the treatment in specialised rooms designed to provide a non-clinical and calming atmosphere where a specially trained therapist was available to provide psychological support. The psychedelic effects of psilocybin last as long as eight hours, and once these had passed the participants were able to return home.